(untitled) - Atrial Fibrillation Network; Bristol-Myers Squibb, Pfizer; Compare apixaban and vitamin-K antagonists in patients with atrial fibrillation (AF) and end-stage kidney disease (ESKD) (AXADIA) (2019)
. Accessed October 5, 2020 at: